- Home
- LTRX vs GALT Comparison
LTRX vs GALT Comparison
Compare LTRX & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LTRX
- GALT
- Stock Information
- Founded
- LTRX 1989
- GALT 2000
- Country
- LTRX United States
- GALT United States
- Employees
- LTRX N/A
- GALT N/A
- Industry
- LTRX Computer Communications Equipment
- GALT Biotechnology: Pharmaceutical Preparations
- Sector
- LTRX Telecommunications
- GALT Health Care
- Exchange
- LTRX Nasdaq
- GALT Nasdaq
- Market Cap
- LTRX 197.5M
- GALT 232.3M
- IPO Year
- LTRX 2000
- GALT N/A
- Fundamental
- Price
- LTRX $4.66
- GALT $5.67
- Analyst Decision
- LTRX Strong Buy
- GALT Strong Buy
- Analyst Count
- LTRX 4
- GALT 3
- Target Price
- LTRX $4.63
- GALT $6.00
- AVG Volume (30 Days)
- LTRX 334.0K
- GALT 339.7K
- Earning Date
- LTRX 11-05-2025
- GALT 11-14-2025
- Dividend Yield
- LTRX N/A
- GALT N/A
- EPS Growth
- LTRX N/A
- GALT N/A
- EPS
- LTRX N/A
- GALT N/A
- Revenue
- LTRX $122,923,000.00
- GALT N/A
- Revenue This Year
- LTRX $4.77
- GALT N/A
- Revenue Next Year
- LTRX $11.90
- GALT N/A
- P/E Ratio
- LTRX N/A
- GALT N/A
- Revenue Growth
- LTRX N/A
- GALT N/A
- 52 Week Low
- LTRX $1.91
- GALT $0.73
- 52 Week High
- LTRX $5.72
- GALT $6.55
- Technical
- Relative Strength Index (RSI)
- LTRX 45.51
- GALT 62.88
- Support Level
- LTRX $4.37
- GALT $5.04
- Resistance Level
- LTRX $5.22
- GALT $5.36
- Average True Range (ATR)
- LTRX 0.26
- GALT 0.33
- MACD
- LTRX -0.04
- GALT 0.05
- Stochastic Oscillator
- LTRX 29.95
- GALT 60.81
About LTRX Lantronix Inc.
Lantronix Inc is a networking company. It provides secure data access and management solutions for the Internet of Things (IoT) and information technology assets. It organizes its products and solutions into three product lines: Embedded IoT Solutions, IoT Systems Solutions, and Software and Services. The IoT System Solutions segment is the key revenue driver for the company. The company serves a diverse range of markets including healthcare, industrial, security, energy, transportation, and government networking. Its primary geographic markets are the Americas, Europe, the Middle East and Africa, and Asia Pacific Japan. The Americas contribute the vast majority of total revenue.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.